The market's sizzle is heating up, and Wall Street's top analysts are pounding the table on an eclectic group of stocks garnering significant buzz. From cutting-edge tech plays to biotech innovators and consumer brands, this diverse basket of eight names stands out amid the recent wave of positive investor sentiment.
While fundamentals and valuations should always be your primary focus, it pays to keep a finger on the market's pulse. Stocks riding upbeat momentum tend to stay hot until the narrative changes. With that in mind, here's a closer look at the potential sizzlers turning heads based on analysts' buy recommendations and upbeat news/data flow:
PagerDuty (PD) - This $1.9 billion software firm helps businesses proactively manage digital operations. Despite an analysts' Hold rating, the recent $23 share price could have further upside if PD's cloud services keep gaining traction.
Datadog (DDOG) - Cloud computing's rise has been a boon for players like $29 billion Datadog and its monitoring/analytics solutions. With robust Buy ratings and a $138.60 average price target, the bulls foresee more potential gains.
The sneaky (yet 100% legal) way for Obama to return to power
![](https://mcusercontent.com/6e7112ee59dfce21b40dd90be/images/f36e96f1-59c3-e39b-f039-8d83a70c51ed.png)
And there's a sneaky (yet 100% legal) way to achieve this. In fact, this disaster scenario is already underway.
See what they're up to, and how you can get ready today.
Here's the full video exposé.
![](https://gallery.mailchimp.com/6e7112ee59dfce21b40dd90be/images/5381a560-c43d-4139-8a39-c27df52cf896.png)
DraftKings (DKNG) - The $19 billion sports betting/daily fantasy sports giant remains a battleground stock. While analysts recommend buying, DKNG's $48.50 price target suggests shares may be undervalued relative to its market position.
Ionis Pharmaceuticals (IONS) - This $6.5 billion biotech focused on novel RNA-targeted therapies has analysts bullish on its $60.20 price target. Positive pipeline updates could catalyze a breakout from the $39 area.
Comerica (CMA) - Analysts are lukewarm on the $8.4 billion regional bank around $41 per share. But strengthening loan growth and moderating credit costs could drive a re-rating if CMA's $57.60 price target proves conservative.
Edwards Lifesciences (EW) - Renaissance in transcatheter heart valve replacements fueled a hot streak for $53 billion medical device maker EW lately. The bulls' $98 target suggests more upside potential ahead.
Moderna (MRNA) - The $60 billion biotech's breakthrough mRNA vaccine platform was a COVID-era success story. Now analysts eye the $145.80 price target amid efforts to expand into new therapeutic areas.
Stellantis (STLA) - While analysts are neutral on the $46 billion automaker around $16, any good news on Stellantis' aggressive EV roadmap could provide a spark toward the $26.93 price objective.
Your vote doesn’t matter Elon Musk: “Biggest Fear…” Full Story >> |
As you can see, this watchlist runs the gamut from small-cap software disruptors and mid-cap biotechs to large-cap stalwarts across banking, healthcare and automotive sectors. The key thread is the combination of upbeat momentum and analyst optimism - two factors that can fuel further gains if sustainable.
Of course, stock prices can be fickle and analyst calls don't always play out as expected. So make sure to carefully evaluate the fundamentals alongside the bubbly sentiment data as you decide which hot tickers to potentially add to your portfolio.
With earning season approaching and the second half underway, this high-conviction group represents an interesting mix of potential trade setups for momentum traders and long-term investment opportunities alike. Stay tuned for more insights, and happy investing!